Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $210000.0.

  • Harvard Bioscience's Change in Receivables rose 3548.39% to $210000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$693000.0, marking a year-over-year increase of 7066.05%. This contributed to the annual value of -$974000.0 for FY2024, which is 2024.69% down from last year.
  • As of Q3 2025, Harvard Bioscience's Change in Receivables stood at $210000.0, which was up 3548.39% from -$1.8 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Change in Receivables high stood at $3.6 million for Q4 2021, and its period low was -$2.8 million during Q2 2024.
  • For the 5-year period, Harvard Bioscience's Change in Receivables averaged around -$278526.3, with its median value being -$584000.0 (2021).
  • In the last 5 years, Harvard Bioscience's Change in Receivables skyrocketed by 21052.63% in 2021 and then crashed by 89731.8% in 2022.
  • Quarter analysis of 5 years shows Harvard Bioscience's Change in Receivables stood at $3.6 million in 2021, then tumbled by 64.12% to $1.3 million in 2022, then dropped by 26.48% to $941000.0 in 2023, then skyrocketed by 147.5% to $2.3 million in 2024, then tumbled by 90.98% to $210000.0 in 2025.
  • Its last three reported values are $210000.0 in Q3 2025, -$1.8 million for Q2 2025, and -$1.4 million during Q1 2025.